This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients’ quality of life by eluding the use of current standard treatments administered by intraocular injections. Madrid, 25 September 2017. Sylentis presents, for the first time, positive data on the efficacy […]
Author Archives: Manuel Simbionte
HELIX is a Phase III clinical trial started by Sylentis with the investigational new drug SYL1001, based on RNA interference technology (RNAi). The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). […]
SYL1001 is a compound under investigation for the treatment of dry eye disease. It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness. At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017, around 11,000 attendees will meet […]
Sylentis reports positive Phase II results with SYL1001 in treating ocular pain related to dry eye syndrome Phase II dose-finding and efficacy trials (SYL1001_II and SYL1001_III) achieved their primary endpoints in terms of ocular pain (VAS) (p<0.016) and hyperaemia reduction with a dose of 1.125% (p<0.0134). SYL1001 was well tolerated at all evaluated doses and […]
All bamosiran doses similarly reduced the intraocular pressure (IOP). In patients with a baseline IOP greater than or equal to 25 mm Hg, 1.125% bamosiran showed more efficacy The trial did not meet the secondary objective of demonstrating non-inferiority compared to timolol in the total patient population; however, bamosiran at dose 1.125% ((450 micrograms) showed […]
Sylentis sponsors the 11th Annual meeting of the Oligonucleotide Therapeutics Society (OTS). The meeting will be held in Leiden (The Netherlands) 11-14th October, 2015. Oligonucleotide Therapeutics Society is an open, nonprofit forum to foster academia and industry-based research and development of oligonucleotide therapeutics. You can find more information about this event on the following webpage: http://www.oligotherapeutics.org/2015-annual-meeting/
The main endpoint of the trial is to establish the most effective dose of bamosiran for reducing intraocular pressure after 28 days’ treatment. The Phase IIb trial with bamosiran will be conducted at 21 centres in Spain, Germany, Estonia and the United States, enrolling 180 patients. Madrid, 17 July 2014: Grupo Zeltia (MC:ZEL) has announced today […]
SYL040012 is a novel compound arising from Sylentis’s research in ophthalmological disorders. It is indicated for treating ocular hypertension associated with glaucoma. SYL040012 is a chemical entity under the heading of interference RNA (RNAi). Sylentis is one of only five companies in the world with RNAi-based products undergoing clinical trials. Madrid, 7 June 2013: Sylentis, a […]
SYL1001 is a compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye. Madrid, 27 February 2013: Sylentis, a biopharmaceutical subsidiary […]
Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an oral communication entitled “Phase I Trial with SYL040012: New RNAi-based treatment for glaucoma” at the 7thConference on Glaucoma, […]
Español